Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06552000 · ClinicalTrials.gov registry record · NA
Pre-operative Tumor Treating Fields in Patients With Resectable Lung Cancer
A NA study, sponsored by University of Texas Southwestern Medical Center.
- Not yet
- Registry status
- NA
- Development phase
- 18
- Enrollment target
NCT06552000: Clinical Trial NA study, sponsored by University of Texas Southwestern Medical Center.
NCT06552000 is a NA study that has not yet begun recruiting, run by University of Texas Southwestern Medical Center. The registered enrollment target is 18 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06552000, a NA study, has not yet begun recruiting, sponsored by University of Texas Southwestern Medical Center.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to study the clinical and biologic effects of Tumor Treatment Fields (TTFields) in patients undergoing resection of stage I-IIIA Non-Small Cell Lung Cancer (NSCLC). TTField is a non-invasive treatment that uses low-intensity electrical fields to treat cancer. Resection is the medical term for surgically removing part or all of a tissue, structure, or organ.
Primary Outcome
Determine the effect of TTFields on expression of Fanconi anemia pathway-associated genes in NSCLC.
Interventions
- DEVICE NovoTTF-200T System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2026-07-01 |
| Est. Completion | 2030-12-01 |
| Phase | NA |
What is known before NCT06552000 opens enrollment
NCT06552000 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which NovoTTF-200T System is the first listed.
NCT06552000 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06552000 about?
NCT06552000 is a clinical study titled "Pre-operative Tumor Treating Fields in Patients With Resectable Lung Cancer". The purpose of this study is to study the clinical and biologic effects of Tumor Treatment Fields (TTFields) in patients undergoing resection of stage I-IIIA Non-Small Cell Lung Cancer (NSCLC). TTField is a non-invasive treatment that uses low-intensity electrical fields to treat cancer. Resection i...
What is the current status of trial NCT06552000?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 18 participants. The study started on 2026-07-01. Estimated completion is 2030-12-01.
What interventions are being tested in trial NCT06552000?
The interventions under investigation include: NovoTTF-200T System (DEVICE).
Who is sponsoring clinical trial NCT06552000?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06552000's enrollment target sits among peer trials
18 1863rd of 2000 higher than 130 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI